The role of ultra-processed food consumption in protein-energy wasting and sarcopenia development in patients with chronic kidney diseases

Zainab Shateri[1†], Sevda Eskandarzadeh[2†], Mehran Nouri[3,4,5], Shahrokh Ezzatzadegan Jahromi[6], Fatemeh Mansouri[7*] and Siavash Babajafari[7,8*]

Abstract

Background The effect of ultra-processed foods (UPFs) on chronic kidney disease (CKD) has been studied in some studies. The present study aimed to investigate the association between UPF consumption and the risk of protein-energy wasting (PEW) and sarcopenia in patients with CKD in the Iranian population.

Methods The current cross-sectional study included 110 patients with CKD referred to two clinics in Shiraz, Iran. The International Society of Renal Nutrition and Metabolism (ISRNM) criteria and the Asian Working Group for Sarcopenia (AWGS) guideline were considered for the diagnosis of PEW and sarcopenia, respectively. The valid semi-quantitative food frequency questionnaire was used to assess participants' dietary intake. The logistic regression was used to examine the association of UPFs with PEW and sarcopenia.

Results We observed no significant association between sarcopenia and PEW with UPFs in the crude model. After adjusting for confounders, we observed a significantly higher odds of sarcopenia in the upper versus lower median of UPF intake (odds ratio (OR) = 3.59, 95% confidence interval (CI): 1.02−12.62, P = 0.046).

Conclusions Our findings suggest a positive relationship between UPF intake and sarcopenia among CKD patients. Therefore, reducing the intake of UPFs may decrease the odds of sarcopenia in patients suffering from CKD.

Keywords Ultra-processed foods, Protein-energy wasting, Sarcopenia, Chronic kidney disease

†Zainab Shateri and Sevda Eskandarzadeh equally contributed to this work.

*Correspondence:
Fatemeh Mansouri
fatemehsh2824@gmail.com
Siavash Babajafari
jafari@sums.ac.ir
[1] Department of Nutrition and Biochemistry, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran
[2] Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
[3] Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
[4] Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
[5] Department of Community Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
[6] Department of Medicine, School of Medicine, Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
[7] Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
[8] Department of Clinical Nutrition, Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

Shateri *et al. BMC Nephrology*   (2024) 25:4

Page 2 of 8

Introduction

Chronic kidney disease (CKD) is one of the most important chronic non-communicable diseases whose prevalence and incidence are increasing [1]. The global burden of CKD increases mainly due to aging, diabetes, infections, hypertension, environmental toxins, and high body mass index (BMI) [2]. The prevalence of this disease is between 11.7% and 15.1% in the world [2].

One of the crucial complications of CKD is protein-energy wasting (PEW), a condition of metabolic and nutritional disorders in which the body's energy reserves and systemic protein are lost simultaneously [3]. PEW occurs due to anorexia, autoimmune conditions, systemic inflammation, and a hypercatabolic state due to uremia [4]. Sarcopenia is another common complication of CKD, with decreased muscle mass, performance, and muscle strength. This disease is associated with cardiovascular complications and increased patient mortality [5].

Diet plays an essential role in CKD. In CKD patients, phosphorus, sodium, and protein consumption is reduced to delay the onset of uremic toxicity, which may have toxic effects on the kidney, heart, and blood vessels [6]. The nutrition transition is happening rapidly in Iran [7]. This concept shows an increased tendency to consume hydrogenated fats, animal fats, sugar-containing products, packaged snacks, low-fiber foods, artificially sweetened beverages, and processed foods. In fact, the modern diet has replaced the traditional diet [8, 9]. Ultra-processed foods (UPFs) are ready-to-heat or ready-to-eat foods [10]; many of these foods are considered nutritionally poor, containing high levels of free sugars, saturated fat, salt, phosphorus, energy, additives, and low levels of micronutrients, protein, and fiber [11–13].

Many epidemiological studies show that UPFs are harmful to human health [12, 14]. The effect of UPFs on CKD has been studied in some investigated [15, 16]. A cross-sectional study showed that more intake of UPFs was associated to a more prevalence ratio of CKD [17]. In a cohort study, the findings indicated that higher consumption of UPFs was associated with a higher risk of CKD [18]. The pathways by which UPF intake may lead to the onset of CKD are not fully understood. However, an animal study suggests that advanced glycation end products (AGEs) derived from processed foods are an important factor in the pathogenesis of CKD by activating the complement pathway and disrupting intestinal barrier permeability [19].

Although there are studies on the effect of UPFs on the risk of CKD, to our knowledge, no study has been conducted on the association of UPF consumption with two important complications of CKD (PEW and sarcopenia). Therefore, the present study aimed to investigate the association between UPF consumption and the odds of PEW and sarcopenia in patients with CKD in the Iranian population.

Methods

Study population

Based on the inclusion and exclusion criteria, the current cross-sectional study included 110 patients with CKD referred to Imam Reza and Motahari clinics in Shiraz (Fars province, Iran). Using statistical software and considering the sample size formula for estimating a proportion, α = 0.05, β = 20%, ratio (p) = 0.5, and 13% drop-out, 110 patients were determined as our final sample size. The present study was conducted between January and October 2022.

Our inclusion criteria were as follows: aged > 18 years, estimated glomerular filtration rate (eGFR) < 60 mL/min/173m^2 by a physician, no cognitive impairments, and willingness to participate in the study.

Also, our exclusion criteria were as follows: undergoing dialysis, suffering from heart failure and liver cirrhosis, presence of active infection, a daily energy intake of ≤ 800 or ≥ 4200 kcal, and remaining more than 40% of the food frequency questionnaire (FFQ) unanswered (Fig. 1). This study was approved by the Medical Research and Ethics Committee of Shiraz University of Medical Sciences (Code: 28190).

Data collection

We used bioelectrical impedance analysis (BIA) (IN BODY-S10) to assess muscle mass and fat percentage and the Omron BF511 scale for weight assessment (with minimal clothes, without shoes, and accuracy of 100 gr). A non-stretchable tape (accuracy of 0.5 cm) was used to measure height and mid-arm circumference (MAC). BMI was calculated by dividing body weight by the square of height. We also collected 5 mL of fasting blood samples from all participants to evaluate creatinine, albumin, and other biochemical variables. Moreover, the physical activity level was assessed by a validated international physical activity questionnaire (IPAQ) [20].

Diagnosis of sarcopenia

The Asian Working Group for Sarcopenia (AWGS) guideline, which considers low muscle mass, low muscle strength, and/or low muscle function as criteria for sarcopenia diagnosis, was used in our study. A dynamometer set measured handgrip strength (HGS) as an indicator of muscle strength. Also, to measure muscle and fat mass, a BIA was used and to assess muscle function, the 5-time chair standing test and the gait speed test were applied (walking speed for 6 m). We considered skeletal muscle mass index (SMI) less than 7 for men and less than 5.7 kg/m^2 for women as the first criteria for sarcopenia.

Fig. 1 Study flow diagram

Secondly, muscle strength less than 28 and 18 for men and women, respectively, and/or weak physical performance (5-time chair standing test more than 12 s or gait speed less than 1 m/s) were considered to approve sarcopenia diagnosis [21].

Diagnosis of PEW

The International Society of Renal Nutrition and Metabolism (ISRNM) criteria were used for PEW diagnosis. The categories recommended by ISRNM for PEW diagnosis are as follows: low protein and energy intake (dietary protein intake (DPI) < 0.6 g/kg/day and dietary energy intake < 25 kcal/kg/day), low BMI (BMI < 23 kg/m^2, unintentional weight loss: 5% over 3 months or 10% over 6 months, total body fat < 10%), biochemical indicators (serum albumin < 3.8 g/dL, serum pre-albumin < 30 mg/dL, and serum cholesterol < 100 mg/dL), and muscle mass wasting (decreased muscle mass 5% over 3 months or 10% over 6 months, decreased mid-arm muscle circumference area (a decrease of more than 10% compared to the 50th percentile of the reference population)), and creatinine appearance 24-h urine (lower quartile based on sex)). We excluded patients with less than 500 mL/day of urine to eliminate concerns about urine collection errors. At least three indicators were considered for diagnosing kidney disease-related PEW [22].

Food grouping and dietary assessment

The valid semi-quantitative FFQ (168 items) was used to assess participants' dietary intake [23]. We also offered participants the household measurement system (like plates, bowls, tablespoons, teaspoons, glasses, and cups) and a validated food album for better estimated the type and size of foods [24]. To measure the amount of food item intake, we converted the recorded values of each food item to grams and multiplied them by daily intake frequency.

The UPF index was calculated by selecting food items that the NOVA system defined as UPFs. UPFs include eight groups (1. non-dairy beverages, 2. cakes and cookies, 3. dairy beverages, 4. fast food and processed meats, 5. oil and sauce, 6. sweets, 7. bread, and 8. etc.) and the items of them are as bellows: processed meats, candies, biscuits, cakes, pastries and sweets, buns, packaged bread, salty snacks, ice cream, industrial fruit drinks, sweetened milk-based beverages, margarine, fries, soft drinks, sauces, dressing, and others. The calorie intake of each UPF item was used to calculate the total daily intake of each one. We divided the average daily calorie intake of each item of UPF groups by the total daily energy intake of UPFs, then multiplied by 100 to estimate the portion of each food group to the total UPF intake. Total UPF calories divided by total caloric intake and multiplied by 100 were used as exposure in our study [12, 25]. Nutritionist IV software for Iranians (version 7.0; N-Squared Computing, Salem, OR, USA) was used in the present study.

Statistical analysis

We used SPSS (version 26) for all the analyses in our study. A p-value less than 0.05 was considered as level of significance. We reported study participants' baseline characteristics based on the median of UPFs as a percentage for categorical and mean ± standard deviation (SD) or median (interquartile range (IQR)) for continuous variables. The logistic regression in crude and adjusted models was used to examine the association between PEW and sarcopenia with UPFs. We adjusted age, sex, energy, and physical activity to eliminate their confounding roles in the final model.

Shateri *et al. BMC Nephrology*   (2024) 25:4

Page 4 of 8

Table 1 Baseline features of the study population across the median of UPFs

Variables	UPFs (energy %)		
	M$_1$ (*n* = 54)	M$_2$ (*n* = 56)	*P*-value
Age (year) [1]	66.00 (21.00)	64.00 (19.00)	0.163
BMI (kg/m^2) [2]	28.25 ± 4.97	27.82 ± 6.28	0.693
Sarcopenia, yes (%) [3]	5 (9.30)	11 (19.60)	0.101
PEW, yes (%) [3]	5 (9.30)	11 (19.60)	0.101
Sex, male (%) [3]	23 (42.60)	37 (66.10)	**0.011**
Muscle weight (kg) [1]	19.70 (7.00)	22.20 (7.40)	**0.033**
Fat percentage (%) [2]	29.34 ± 8.69	25.13 ± 10.01	**0.020**
MAC (cm) [1]	29.00 (6.00)	29.00 (5.00)	0.757
ASM (kg/m^2) [2]	8.26 ± 1.39	8.34 ± 1.68	0.763
HGS (kg) [1]	15.50 (10.00)	18.00 (12.00)	0.091
Walk duration (second) [1]	7.00 (1.00)	7.00 (2.00)	0.441
Chair sitting (second) [1]	14.00 (3.30)	13.50 (5.00)	0.521
SGA [1]	8.50 (4.00)	9.50 (4.00)	0.170
Smoking, yes (%) [3]	11 (20.40)	12 (21.40)	0.539
Physical activity (%) [3]			0.124
Low	42 (77.80)	37 (66.10)	
Moderate	12 (22.20)	19 (33.90)	
Marital status (%) [3]			0.520
Single	3 (5.60)	4 (7.10)	
Married	51 (94.40)	52 (92.90)	
eGFR (mL/min/1.7m^2) [2]	29.82 ± 11.26	35.39 ± 14.93	**0.029**
Hemoglobin (gr/dL) [2]	12.24 ± 2.00	12.83 ± 2.25	0.152
Albumin (gr/dL) [2]	4.09 ± 0.42	4.08 ± 0.43	0.968
Iron (µg/dL) [2]	75.05 ± 35.63	70.37 ± 33.96	0.544
Ferritin (ng/mL) [2]	151.55 ± 139.69	101.79 ± 102.55	**0.046**
TIBC (mcg/dL) [1]	289.00 (79.00)	331.00 (86.00)	0.097
ALT (IU/L) [2]	21.57 ± 8.62	23.34 ± 11.87	0.437
AST (IU/L) [1]	20.00 (9.00)	21.00 (6.00)	0.715
PTH (pg/mL) [1]	71.20 (59.90)	46.00 (39.10)	**0.003**
Vitamin D$_3$ level (ng/mL) [2]	37.44 ± 15.38	32.25 ± 14.92	0.081
BUN (mg/dL) [2]	32.77 ± 15.96	31.25 ± 14.84	0.605
Creatinine (mg/dL) [1]	21.30 (0.99)	1.92 (0.90)	0.669
Urine creatinine (mg/dL) [2]	868.35 ± 396.07	872.26 ± 394.41	0.959
FBS (mg/dL) [1]	99.00 (51.00)	96.00 (18.00)	0.736
TG (mg/dL) [2]	142.78 ± 70.71	158.57 ± 105.15	0.399
Total cholesterol (mg/dL) [2]	154.04 ± 39.53	149.77 ± 38.17	0.566
LDL-C (mg/dL) [2]	87.95 ± 26.73	80.45 ± 26.51	0.190
HDL-C (mg/dL) [2]	42.31 ± 9.65	43.13 ± 15.25	0.766
PCO$_2$ (mmHg) [2]	41.02 ± 5.66	47.42 ± 53.94	0.388
PO$_2$ (mmHg) [1]	29.60 (17.80)	34.60 (15.00)	0.097
HCO$_3$ (mmol/L) [2]	23.38 ± 3.59	21.79 ± 3.42	**0.019**
UPFs (kcal) [1]	118.10 (62.88)	264.39 (134.60)	**<0.001**

BMI Body mass index, *PEW* Protein-energy wasting, *MAC* Mid-arm circumference, *ASM* Appendicular skeletal muscle mass, *HGS* Handgrip strength, *SGA* Subjective global assessment, *eGFR* Estimated glomerular filtration rate, *TIBC* Total iron-binding capacity, *ALT* Alanine transaminase, *AST* Aspartate transaminase, *PTH* Parathyroid hormone, *BUN* Blood urea nitrogen, *FBS* Fasting blood sugar, *TG* Triglyceride, *LDL-C* Low-density lipoprotein cholesterol, *HDL-C* High-density

Table 1 (continued)

lipoprotein cholesterol, *UPFs* Ultra-processed foods, *PCO$_2$* Partial pressure of carbon dioxide, *PO$_2$* Partial pressure of oxygen

Values are mean ± SD or median (IQR) for continuous and percentage for categorical variables

[1] Using Mann–Whitney U test for abnormal continuous variables. Values are median (IQR)

[2] Using independent samples T-test for normal continuous variables. Values are mean ± SD

[3] Using chi-square test for categorical variables. Values are percentages

Results

According to Table 1, there were significant differences between sex (*P* = 0.011), muscle mass (*P* = 0.033), fat percentage (*P* = 0.020), estimated glomerular filtration rate (eGFR) (*P* = 0.029), ferritin (*P* = 0.046), parathyroid hormone (PTH) (*P* = 0.003), HCO$_3$ (*P* = 0.019), and UPF intake (*P* < 0.001) between the lower and upper median of UPF intake. The baseline characteristics of the study participants are reported in Supplementary Table 1.

The intake of macronutrients and UPF subgroups across the median of UPF intake are presented in Figs. 2 and 3. As shown in Fig. 2, the intake of protein, monounsaturated fatty acids (MUFAs), and polyunsaturated fatty acids (PUFAs) did not significantly differ between UPF median (P > 0.05), but there was a significant difference in carbohydrate and saturated fatty acid (SFA) intake (*P* = 0.017 and *P* = 0.014, respectively). The contribution of macro- and micronutrient intake by the median of UPFs is shown in Supplementary Table 2.

In multivariate analysis (Table 2), we observed no significant association between UPFs and sarcopenia and PEW in the crude model. After adjusting for age, sex, smoking, and energy intake, we observed a significantly higher odds of sarcopenia in the upper versus lower median of UPF intake (odds ratio (OR) = 3.59, 95% confidence interval (CI): 1.02–12.62, *P* = 0.046).

Discussion

Our results showed a direct association between the consumption of UPFs and sarcopenia in adults with CKD after adjusting confounders. According to our results, higher UPF intake leads to 3.59 times increased odds of sarcopenia. However, we did not find any association between the consumption of UPFs and PEW odds.

Evidence suggests that intake of UPFs may cause an increased risk of non-communicable diseases [26]. Based on our knowledge, the current study is the first to assess the association between UPF consumption and sarcopenia and PEW odds in CKD patients.

Some of the characteristics of UPFs, such as affordability, palatability, availability, convenience, and high supply in the market, lead to their overconsumption [27]. UPFs

**Fig. 2** The contribution of macronutrient intake based on UPF median

Fig. 3 Participants' food group intake across median of UPFs

Shateri *et al. BMC Nephrology*   (2024) 25:4

Page 6 of 8

Table 2 Crude and multivariable-adjusted odds ratios and 95% CIs across the median of energy percent of UPFs

Median of UPFs	Abnormal/normal	Crude Model		Adjusted Model	
		OR	95% CI	OR	95% CI
Sarcopenia					
M_1	5/49	Ref	-	Ref	-
M_2	11/45	2.39	0.77–7.43	**3.59**	**1.02–12.62**
P-value		0.130		**0.046**	
Protein-energy wasting					
M_1	5/49	Ref	-	Ref	-
M_2	11/45	2.39	0.77–7.43	2.86	0.87–9.40
P-value		0.130		0.083	

UPFs: Ultra-processed foods

Obtained from logistic regression

These values are odds ratio (95% CIs)

Significant values are shown in bold

Adjusted for age, sex, smoking, and energy intake

are dense in calories and poor in protein, fiber, vitamins, minerals, and other phytochemicals [28], which are essential nutrients for muscle health [29]. Our study results showed an association between higher consumption of UPFs and sarcopenia in CKD patients. Only one study has investigated the association between these two variables. This cross-sectional study showed that the elderly who consumed UPFs more than 1–2 times a week had a higher chance of developing sarcopenia. Also, their results indicated that the probability of sarcopenia in the elderly increases even with low exposure to UPFs [30].

Wasting of muscle mass, a common criterion of sarcopenia and PEW, is frequently found in CKD patients, especially in those with more advanced stages of the disease. On the other hand, decreased body fat is more common in PEW than in sarcopenia [31]. Etiological factors leading to sarcopenia and PEW associated with CKD that are exacerbated by consumption of UPFs include the following: developed insulin resistance, acidosis, vitamin D deficiency, and disruption of hormones like testosterone, insulin growth factor-1 (IGF-1), and growth hormone (GH) resistance [32, 33]. In addition, the change in the gut microbiome and dysfunction of the gut barrier aggregated by exposure to phthalates, which leaks into food through contact materials or food processing plastics, leads to the development of an inflammatory environment (increased levels of pro-inflammatory cytokines levels such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6)) [34, 35] as a contributor to muscle wasting [36, 37]. One study has reported an association between phthalate exposure and lower grip strength, a marker of muscle health and sarcopenia [38]. Lower fiber intake also leads to the accumulation of protein

fermentation metabolites, uremic toxicity [39], and finally, uremic muscle wasting [40].

We did not find a significant association between UPF intake and PEW in patients with CKD. To our knowledge, this is the first study that assessed this association. Mechanisms contributing to PEW are the same as sarcopenia etiology [31], but energy imbalance leading to fat loss could be a more important factor in PEW etiology. Even though, higher PEW was observed in the higher UPF intake group, no significant difference between protein and energy intake was found between the two UPF groups. Furthermore, UPFs contain a high amount of added sugars, trans and SFAs, and additives like emulsifiers, preservatives, stabilizers, and artificial flavors, which enhance lipogenesis (contrary to PEW criteria) and disrupt muscle protein synthesis and ultimately lead to a decline in muscle mass (in line with PEW criteria) [31], resultant of these two may be the reason why we did not observe a significant association between PEW and UPF intake.

We can mention some limitations of the present study. The investigation to the effect of UPF intake on inflammation as a determinant of CKD complications because of the lack of data on inflammatory factors such as nuclear factor-κB (NF-κB), C-reactive protein, and IL-6 were impossible. However, the effects of some confounders were adjusted in the analysis; there may be other unknown confounding factors in this study.

Conclusions

In conclusion, our findings suggest a positive association between UPF intake and sarcopenia among CKD patients. Therefore, reducing the intake of UPFs may decrease the odds of sarcopenia in patients suffering from CKD. The importance of restricting access to UPFs should be addressed by public policy.

Availability of data and methods

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12882-023-03409-6.

Additional file 1: Table S1. Baseline features of the study population. **Table S2.** Macro- and micronutrient intake by the median of UPFs.

Shateri *et al. BMC Nephrology*   (2024) 25:4

Page 7 of 8

Authors' contributions

Z.S, S.E, S.E.J and M.N; Contributed to writing the first draft. M.N; Contributed to all data, statistical analysis, and interpretation of data. F.M and S.B; Contributed to the research concept, supervised the work, and revised the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Declarations

Ethics approval and consent to participate

This study was approved by the medical research and ethics committee of Shiraz University of Medical Sciences and the informed consents were completed by all participants. Also, we confirmed all the methods included in this study are in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Competing interests

Not applicable.

References

1. Abreu IS, Nascimento LC. Lima RAGd, Santos CBd: Children and adolescents with chronic kidney disease in haemodialysis: perception of professionals. Rev Bras Enferm. 2015;68:1020–6.
2. Lv J-C, Zhang L-X. Prevalence and disease burden of chronic kidney disease. Renal fibrosis: mechanisms and therapies. 2019:3–15.
3. Hanna RM, Ghobry L, Wassef O, Rhee CM, Kalantar-Zadeh K. A practical approach to nutrition, protein-energy wasting, sarcopenia, and cachexia in patients with chronic kidney disease. Blood Purif. 2020;49(1–2):202–11.
4. Obi Y, Qader H, Kovesdy CP, Kalantar-Zadeh K. Latest consensus and update on protein energy-wasting in chronic kidney disease. Curr Opin Clin Nutr Metab Care. 2015;18(3):254.
5. Souza VAd, Oliveira Dd, Mansur HN, Fernandes NMdS, Bastos MG. Sarcopenia in chronic kidney disease. Braz J Nephrol. 2015;37:98–105.
6. Apetrii M, Timofte D, Voroneanu L, Covic A. Nutrition in chronic kidney disease—the role of proteins and specific diets. Nutrients. 2021;13(3):956.
7. Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr. 2002;5(1a):149–55.
8. Popkin BM. Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases–. Am J Clin Nutr. 2006;84(2):289–98.
9. Drewnowski A. Nutrition transition and global dietary trends. Nutrition. 2000;7(16):486–7.
10. Lane KE, Davies IG, Darabi Z, Ghayour-Mobarhan M, Khayyatzadeh SS, Mazidi M. The association between ultra-processed foods, quality of life and insomnia among adolescent girls in Northeastern Iran. Int J Environ Res Public Health. 2022;19(10):6338.
11. Gibney MJ. Ultra-processed foods: definitions and policy issues. Current Developments Nutrition. 2019;3(2):nzy077.
12. Monteiro CA, Cannon G, Levy RB, Moubarac J-C, Louzada ML, Rauber F, Khandpur N, Cediel G, Neri D, Martinez-Steele E. Ultra-processed foods: what they are and how to identify them. Public Health Nutr. 2019;22(5):936–41.
13. Montero-Salazar H, Donat-Vargas C, Moreno-Franco B, Sandoval-Insausti H, Civeira F, Laclaustra M, Guallar-Castillón P. High consumption of ultra-processed food may double the risk of subclinical coronary atherosclerosis: the Aragon Workers' Health Study (AWHS). BMC Med. 2020;18:1–11.
14. Baker P, Friel S. Food systems transformations, ultra-processed food markets and the nutrition transition in Asia. Glob Health. 2016;12:1–15.
15. Rey-García J, Donat-Vargas C, Sandoval-Insausti H, Bayan-Bravo A, Moreno-Franco B, Banegas JR, Rodríguez-Artalejo F, Guallar-Castillón

P. Ultra-processed food consumption is associated with renal function decline in older adults: a prospective cohort study. Nutrients. 2021;13(2):428.
16. Cai Q, Duan M-J, Dekker LH, Carrero JJ, Avesani CM, Bakker SJ, de Borst MH, Navis GJ. Ultraprocessed food consumption and kidney function decline in a population-based cohort in the Netherlands. Am J Clin Nutr. 2022;116(1):263–73.
17. Kityo A, Lee S-A. The intake of ultra-processed foods and prevalence of chronic kidney disease: the health examinees study. Nutrients. 2022;14(17):3548.
18. Gu Y, Li H, Ma H, Zhang S, Meng G, Zhang Q, et al. Consumption of ultraprocessed food and development of chronic kidney disease: the Tianjin Chronic Low-Grade Systemic Inflammation and Health and UK Biobank Cohort Studies. Am J Clin. 2023;117(2):373–82.
19. Snelson M, Tan SM, Clarke RE, De Pasquale C, Thallas-Bonke V, Nguyen T-V, et al. Processed foods drive intestinal barrier permeability and microvascular diseases. Sci Adv. 2021;7(14):eabe4841.
20. Moghaddam MB, Aghdam FB, Jafarabadi MA, Allahverdipour H, Nikookheslat SD, Safarpour S. The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18(8):1073–80.
21. Chen L-K, Woo J, Assantachai P, Auyeung T-W, Chou M-Y, Iijima K, Jang HC, Kang L, Kim M, Kim S. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J American Medical Directors Assoc. 2020;21(3):300–7.
22. Gracia-Iguacel C, González-Parra E, Mahillo I, Ortiz A. Criteria for classification of protein–energy wasting in dialysis patients: impact on prevalence. Br J Nutr. 2019;121(11):1271–8.
23. Mirmiran P, Esfahani FH, Mehrabi Y, Hedayati M, Azizi F. Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. Public Health Nutr. 2010;13(5):654–62.
24. Ghaffarpour M, Houshiar-Rad A, Kianfar H. The manual for household measures, cooking yields factors and edible portion of foods. Tehran Nashre Olume Keshavarzy. 1999;7(213):42–58.
25. Monteiro CA, Cannon G, Moubarac J-C, Levy RB, Louzada MLC, Jaime PC. The UN Decade of Nutrition, the NOVA food classification and the trouble with ultra-processing. Public Health Nutr. 2018;21(1):5–17.
26. Pagliai G, Dinu M, Madarena M, Bonaccio M, Iacoviello L, Sofi F. Consumption of ultra-processed foods and health status: a systematic review and meta-analysis. Br J Nutr. 2021;125(3):308–18.
27. Gibney MJ. Ultra-processed foods: definitions and policy issues. Curr Dev Nutr. 2019;3(2):nzy077.
28. Martini D, Godos J, Bonaccio M, Vitaglione P, Grosso G. Ultra-processed foods and nutritional dietary profile: a meta-analysis of nationally representative samples. Nutrients. 2021;13(10):3390.
29. McGlory C, van Vliet S, Stokes T, Mittendorfer B, Phillips SM. The impact of exercise and nutrition on the regulation of skeletal muscle mass. J Physiol. 2019;597(5):1251–8.
30. de Almeida HC, da Silva Lage VK, de Paula FA. Freitas JdPC, Moreno LG, De Oliveira VC, de Carvalho Bastone A, Santos JNV, Lima LP, Fernandes AC: Association between ultra-processed foods frequency of intake and sarcopenia in older adults: a cross-sectional study. Research, Society and Development. 2022;11(11):e60111133129–e60111133129.
31. Sabatino A, Cuppari L, Stenvinkel P, Lindholm B, Avesani CM. Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol. 2021;34(4):1347–72.
32. Avesani CM, Cuppari L, Nerbass FB, Lindholm B, Stenvinkel P. Ultraprocessed food and chronic kidney disease - double trouble. Clin Kidney J. 2023;16(11):1723–36.
33. Menezes CA, Magalhães LB, da Silva JT, da Silva Lago RMR, Gomes AN, Ladeia AMT, Vianna NA, Oliveira RR. Ultra-processed food consumption is related to higher trans fatty acids, sugar intake, and micronutrient-impaired Status in schoolchildren of Bahia, Brazil. Nutrients. 2023;15(2):381.
34. Cuevas-Sierra A, Milagro FI, Aranaz P, Martínez JA, Riezu-Boj JI. Gut microbiota differences according to ultra-processed food consumption in a Spanish population. Nutrients. 2021;13(8):2710.
35. Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25(4):657–70.

36. Dalle S, Koppo K. Is inflammatory signaling involved in disease-related muscle wasting? Evidence from osteoarthritis, chronic obstructive pulmonary disease and type II diabetes. Exp Gerontol. 2020;137:110964.
37. Schaap LA, Pluijm SM, Deeg DJ, Harris TB, Kritchevsky SB, Newman AB, Colbert LH, Pahor M, Rubin SM, Tylavsky FA. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontology Series A: Biomed Scie Medical Scie. 2009;64(11):1183–9.
38. Sun L, Fan J, Song G, Cai S, Fan C, Zhong Y, Li Y. Exposure to phthalates is associated with grip strength in US adults. Ecotoxicol Environ Saf. 2021;209:111787.
39. Sabatino A, Regolisti G, Brusasco I, Cabassi A, Morabito S, Fiaccadori E. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant. 2014;30(6):924–33.
40. Nishi H, Takemura K, Higashihara T, Inagi R. Uremic Sarcopenia: Clinical Evidence and Basic Experimental Approach. Nutrients. 2020;12(6):1814.

Publisher's Note